CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

ABSTRACT

Although treatment with immune checkpoint inhibitors provides promising benefit for patients with cancer, optimal use is encumbered by high resistance rates and requires a thorough understanding of resistance mechanisms. We observed that tumors treated with PD-1/PD-L1 blocking antibodies develop resistance through the upregulation of CD38, which is induced by all-trans retinoic acid and IFNβ in the tumor microenvironment. In vitro and in vivo studies demonstrate that CD38 inhibits CD8+ T-cell function via adenosine receptor signaling and that CD38 or adenosine receptor blockade are effective strategies to overcome the resistance. Large data sets of human tumors reveal expression of CD38 in a subset of tumors with high levels of basal or treatment-induced T-cell infiltration, where immune checkpoint therapies are thought to be most effective. These findings provide a novel mechanism of acquired resistance to immune checkpoint therapy and an opportunity to expand their efficacy in cancer treatment.

SIGNIFICANCE: CD38 is a major mechanism of acquired resistance to PD-1/PD-L1 blockade, causing CD8+ T-cell suppression. Coinhibition of CD38 and PD-L1 improves antitumor immune response. Biomarker assessment in patient cohorts suggests that a combination strategy is applicable to a large percentage of patients in whom PD-1/PD-L1 blockade is currently indicated. Cancer Discov; 8(9):1156–75. ©2018 AACR.

See related commentary by Mittal et al., p. 1066.

INTRODUCTION

Although strategies incorporating immune checkpoint inhibition, e.g., PD-1/PD-L1 blockade, are achieving unprecedented success, high rates of resistance still limit their efficacy (1–3). Using Kras/Trp53-mutant genetically engineered murine (KP tumor) and Lewis lung cancer (LLC tumor) models of non–small cell lung cancer (NSCLC), we have previously shown that the response to anti–PD-L1 treatment is dependent upon epigenetic regulation of tumor cell PD-L1 (4, 5). We used these well-established NSCLC tumor models and melanoma tumor models to further study immunotherapy resistance.

CD38 is a member of the ribosyl cyclase family that is widely expressed on the surface of nonhematopoietic cells and diverse immune cells. As an ectozyme, CD38 converts NAD+ to ADP-ribose (ADPR) and cADPR, which are essential for the regulation of extracellular metabolites, intracellular Ca2+, cell adhesion, and signal transduction pathways (6). The receptor/ligand activity of CD38 has been documented in multiple immune cell types, and the function varies during lymphocyte development, activation, and differentiation (7). However, its potential function on tumor cells has not been fully elaborated.

Here, we report that tumors gain resistance to PD-L1/PD-1 blockade over time, and that CD38 upregulation on tumor cells is induced by all-trans retinoic acid (ATRA) and IFNβ. CD38 expression mediates suppression via adenosine receptor signaling on cytotoxic T cells. CD38 manipulation was sufficient to regulate CD8+ T-cell proliferation, antitumor cytokine secretion, and killing capability. Pathologic analysis of lung cancer specimens revealed positive immunohistochemical (IHC) staining for CD38 on tumor cells in 15% to 23% of cases, and bioinformatic analyses of patient data sets of NSCLC and melanoma revealed a strong correlation between CD38 expression and an inflamed microenvironment. To test whether CD38 blockade might be efficacious to counter the resistance, we used combination therapy with anti-CD38, or alternatively with an adenosine receptor antagonist, and anti–PD-L1 in lung cancer animal models and demonstrated therapeutic benefit.

RESULTS

Resistance to PD-1/PD-L1 Blockade Results from CD38 Upregulation Mediated by ATRA and IFNβ in Tumors

Our previous data demonstrated suppression of tumor growth and metastases with anti–PD-L1 antibody treatment,
but the lack of complete durable responses (4, 5) suggested the existence of antecedent or acquired resistance mechanisms that subvert enhanced infiltration of effector T cells. We adopted a parallel approach to discover these additional mechanisms, first by long-term pharmacologic treatment of animals with anti–PD-L1 or anti–PD-1 antibody, and second by testing of syngeneic tumors with PD-L1 knockout (KO). Despite initial suppression of tumors by anti–PD-L1, progressive resistance developed in tumor models over 5 to 7 weeks of treatment (Fig. 1A; Supplementary Fig. S1A). By week 7 for the KP and week 5 for the LLC tumor models, there were no significant differences between the isotype control and the treatment groups (Fig. 1A). Week 5 and 7 samples from the 344SQ tumors were used for mRNA profiling (Supplementary Fig. S2A–S2E), representing the respective time points of greatest observed difference in tumor growth and the point at which the anti–PD-L1–treated samples displayed complete resistance. Using a fold-change cutoff of 2.0, a total of 412 genes with FDR ≤ 0.05 (P < 0.035) were found to be differentially expressed between anti–PD-L1 and isotype treated tumors at week 5 (Supplementary Table S1). Comparing the top 200 differentially expressed genes (100 upregulated and 100 downregulated, as depicted in the volcano plot in Supplementary Fig. S2C) versus the results of gene set enrichment analysis (GSEA) and Ingenuity pathway analysis (IPA) on the entire set of differentially expressed genes, and finally versus results of proteomic analysis by reverse-phase protein array (RPMA), we identified CD38 as the only prominently upregulated gene/protein identified in all analyses (Fig. 1B; Supplementary Fig. S2C–S2M, Supplementary Tables S2–S6). Its expression also temporally occurred by week 5 of anti–PD-L1 antibody treatment, along with consistent mRNA changes of CD38-related genes (6, 8–14), and therefore preceded the observed acquisition of tumor resistance (Fig. 1B). Both qPCR and FACS analyses confirmed that CD38 mRNA and protein levels were significantly increased on anti–PD-L1–resistant tumor cells (Fig. 1B and C; Supplementary Fig. S1B). We found similar resistance and upregulation of CD38 with several KP lung tumor models and the B16 melanoma model treated with either anti–PD-1 or anti–PD-L1 (Supplementary Fig. S3A–S3E).

Because our previous reports and work from other labs emphasize the dominant role of PD-L1 expression on tumor cells in mediating tumor immune escape (refs. 4, 15, 16; Supplementary Fig. S4A and S4B), we also used a genetic approach to block PD-L1–mediated signaling. We generated lung cancer cell lines (LLC)JSP and the KP model 531LN3) and the melanoma cell line B16 with PD-L1 knockout by CRISPR/Cas9 editing and tested them in syngeneic PD-L1 wild-type (WT) or PD-L1 KO mice. Both partial PD-L1 signaling blockade (PD-L1 KO cancer cells implanted in PD-L1 wild-type mice) and complete blockade (PD-L1 KO cancer cells implanted in PD-L1 KO mice) partially suppressed tumor growth in a CD8+ T-cell–dependent manner (Supplementary Figs. S4C–S4F, and S5), but resulted in ~4- to 6-fold CD38 upregulation versus the same cells grown in vitro (Fig. 1D and E; Supplementary Fig. S3F). Consistent with these findings, anti–PD-L1 antibody treatment in the autochthonous KP model over 12 weeks showed no durable effect on tumor growth or animal survival, but we observed a significant increase in CD38 on tumor cells in the PD-L1 treatment group (Fig. 1F; Supplementary Figs. S1C–S1D). The consistency of the results between pharmacologic and genetic blockade of PD-L1/PD-L1 in syngeneic and autochthonous models of lung cancer and melanoma indicated that CD38 could represent an important pathway in the development of resistance.

To investigate how CD38 is upregulated on tumor cells, we tested cocultures of tumor cells with activated CD8+ T cells and found a significant increase of CD38 mRNA and protein (Fig. 1G), which was further enhanced by the addition of anti–PD-L1 and similar to the upregulation observed in tumors (Fig. 1D and E; Supplementary Fig. S3). Altogether, the data suggest that the activated T cells in the inflammatory tumor microenvironment stimulate CD38 expression. This finding prompted us to explore the potential mechanism(s) of CD38 upregulation. Prior literature suggests that CD38 is regulated by several soluble factors that may be present in the tumor microenvironment, including ATRA and IFNβ (17–20).

Analysis of the metabolites in anti–PD-L1 treated or PD-L1 KO tumors demonstrated an enrichment of ATRA and an increase in the mRNA for RBP4 and STRA6 that regulate cellular retinol uptake (ref. 21; Fig. 1H and I; Supplementary Fig. S6A–S6B). When human or murine lung cancer lines expressing retinoic acid receptor alpha (RARα) were treated with ATRA for 3 days, CD38 was upregulated in a dose-dependent manner (Fig. 1J and K; Supplementary Fig. S6C). In syngeneic animal tumor models, CD38 on tumor cells was significantly upregulated after 2 weeks of ATRA treatment versus vehicle control, whereas treatment with the RARα antagonist BMS195614 inhibited the CD38 upregulation (Fig. 1L). In addition, we used the tumor lysates to perform ELISA-based assays and found a significant increase of IFNβ in anti–PD-L1–treated tumors (Supplementary Fig. S7A). Upon culturing with IFNβ for 3 days, surface CD38 was significantly increased on multiple cancer lines (Supplementary Fig. S7B). When KP-derived 344SQ tumor-bearing mice were treated with anti–PD-L1 and mRNA profiling was performed by NanoString, we observed an increase of IRF1, which was confirmed by qPCR for IRF1, IRF2, and IRF3 (Supplementary Fig. S8). IRF1 is a transcription factor and tumor suppressor involved in cell growth regulation and immune responses that is induced by ATRA and is essential for the induced expression of IFNβ (22–25). This provides a connection between the independent observations that ATRA and IFNβ are upregulated and produce upregulation of CD38 expression on tumor cells. IFNγ, TNFα, IL-2, and IL-18 are potent antitumor cytokines also documented to induce CD38 in other cell types. We tested if these cytokines modulate CD38 expression in our models, but did not observe effects on CD38 expression in two lung cancer models (Supplementary Fig. S9). Taken together, PD-L1/PD-L1 blockade results in an infiltration of activated T cells and inflammatory changes that lead to ATRA and IFNβ-mediated CD38 upregulation.

**CD38 Suppresses CD8+ T-cell Function via Adenosine Receptor Signaling**

Despite the CD8+ T-cell–dependent effect of anti–PD-L1 antibody during the first 2- to 5-week treatment period (Fig. 2A), which we previously published (4), over time the treatment group showed reduced CD8+ T-cell infiltration into tumors, accompanied by a decrease in CD44CD62L™ memory (48.6% vs. 28.4%) and Ki67+ proliferative CD8+ T cells (18.8% vs. 6.46%), and an increase in exhausted CD8+ T cells.
Figure 1. PD-1/PD-L1 blockade resistance results from CD38 upregulation due to the enrichment of ATRA in tumors. A, Left, anti–PD-L1 antibody (9G2) or an IgG control was injected into 129/Sv mice (200 μg; intraperitoneally) once a week for 4 weeks after 344SQ tumor cells were subcutaneously implanted (1 × 10^6 cells per mouse). Tumors were measured once a week for 8 weeks. The tumor growth curve is shown, with tumor sizes (n = 6 or 7) presented as mean ± SEM. ns, no significant difference; *, P < 0.05; **, P < 0.01. Right, anti–PD-L1 antibody or an IgG control was injected into C57BL/6 mice (200 μg intraperitoneally) once a week for 5 weeks beginning on day 7 after the subcutaneous implantation of LLC-JSP tumor cells (0.5 × 10^6 cells per mouse). Tumors were measured once a week for 6 weeks. The tumor growth curve is shown, with tumor sizes (n = 10 or 11) presented as mean ± SEM, no significant difference; *, P < 0.05. B, Left, Venn diagram of genes changed upon anti–PD-L1 antibody treatment in 344SQ tumors (n = 3) at week 5. The top 100 upregulated genes and top 100 downregulated genes were included from the Volcano plot analysis, 98 genes involved in T-cell activity from GSEA, and the top 19 networks identified with IPA software. Seventy-four protein markers involved in immune signaling pathways, cell-cycle signaling, and tumor metabolism signaling were included for RPPA. CD38 is the only molecule overlapping in all 4 analyses. Middle, heat map showing differentially expressed mRNAs related to CD38 from the two profiled groups. Right, relative Cd38 mRNA levels in sorted 344SQ tumor cells (CD31+CD45−EPCAM+ for sorting) were quantified by qPCR assays using the tumor samples at week 5 (n = 3) from the control and anti–PD-L1 groups. mRNA levels are normalized to L32. C, 344SQ tumors in A were harvested, and CD38 expression on sorted tumor cells was analyzed by FACS at week 5, and represented on the left. LLC-JSP tumors in A were harvested, and CD38 expression on tumor cells was analyzed by FACS at week 4, and represented on the right. D, In immune competent C57BL/6 PD-L1 WT mice (n = 11 or 13), Lewis lung LLC-JSP cells with wild-type PD-L1 or PD-L1 KO (1 × 10^6 cells per mouse) were subcutaneously injected. Mice were sacrificed 4 weeks after injection. The primary tumor mass is shown on the left, presented as mean ± SEM. CD38 mRNA levels quantified with qPCR assay in sorted tumor cells are shown in the right. In C57BL/6 PD-L1 KO mice (n = 6 or 10), Lewis lung LLC-JSP cells with wild-type PD-L1 or PD-L1 KO (1 × 10^6 cells per mouse) were subcutaneously injected. Mice were sacrificed 4 weeks after injection. The primary tumor mass is shown on the left, presented as mean ± SEM. CD38 mRNA levels quantified with qPCR assay in sorted tumor cells are shown in the right. E, In immune competent C57BL/6 PD-L1 WT mice (n = 6 or 7), melanoma B16 cells with wild-type PD-L1 or PD-L1 KO (2 × 10^6 cells per mouse) were subcutaneously injected. Mice were sacrificed 4 weeks after injection. The primary tumor mass is shown on the left, presented as mean ± SEM. CD38 mRNA levels quantified with qPCR assay in sorted tumor cells are shown in the right. F, In immune competent C57BL/6 PD-L1 WT mice (n = 6 or 7), melanoma B16 cells with wild-type PD-L1 or PD-L1 KO (2 × 10^6 cells per mouse) were subcutaneously injected. Mice were sacrificed 4 weeks after injection. The primary tumor mass is shown on the left, presented as mean ± SEM. CD38 mRNA levels quantified with qPCR assay in sorted tumor cells are shown in the right. The primary tumor mass is shown on the left, presented as mean ± SEM. CD38 mRNA levels quantified with qPCR assay in sorted tumor cells are shown in the right.
Chen et al. L cells per mouse). The tumors were harvested to measure the concentration of ATRA on week 5 after tumor cell inoculation. Tumor lysates were used to

body (Ab) or an IgG control (IgG; 200 μg/mL) for 3 days. The nonadherent CD8 T cells in the presence of anti-CD3 (5 μg/mL), and anti–PD-L1 anti-

H, g/mL) for 3 days. The nonadherent CD8 T cells were washed away and cancer cells were harvested for qRT-PCR and FACS analysis. The experiments were repeated three times. Data were analyzed using ANOVA test. H, The indicated tumor-bearing mice were treated with anti–PD-L1 antibody (Ab) or an IgG control (IgG; 200 μg intraperitoneally) once a week for 4 weeks beginning on day 7 after tumor cells were subcutaneously implanted (1 × 10^6 cells per mouse). The tumors were harvested to measure the concentration of ATRA on week 5 after tumor cell inoculation. Tumor lysates were used to measure the concentration of ATRA using the Thermo Orbitrap Fusion Tribrid Mass Spectrometer. The concentrations of ATRA in tumors are presented as mean ± SD with P values. I, Tumors were harvested on week 5 after PD-L1^WT^531LN3, PD-L1^KO^531LN3, PD-L1^WT^LLC-JSP, and PD-L1^KO^LLC-JSP cells (1 × 10^6 cells per mouse) were subcutaneously implanted into syngeneic mice. Tumor lysates were used to measure the concentration of ATRA using the Thermo Orbitrap Fusion Tribrid Mass Spectrometer. The concentrations of ATRA in tumors are presented as mean ± SD with P values. J, The RARA mRNA levels in a panel of lung cancer cell lines (left, murine cancer lines; right, human cancer lines) was measured by qPCR assays. mRNA levels were normalized to L32. The summarized data from 3 independent experiments are shown. K, Cells were incubated with ATRA at different concentrations (0, 100, and 250 nmol/L) for 3 days and stained with anti–CD38 antibody for FACS analysis. CD38 surface expression was quantified by the ratio of mean fluorescence intensity (MFI). The experiments were repeated 3 times. L, The indicated tumor-bearing mice (LLC-JSP bearing C57BL/6 mice; ED1-SQ4 bearing FVB mice; 344SQ bearing 129/Sv mice) were treated with vehicle, ATRA (45 μg in 100 μL 1% methylcellulose; oral administration) or RARα antagonist BMS195614 (67 μg in 100 μL 1% methylcellulose; oral administration) once a day for 2 weeks beginning on day 4 after tumor cells were subcutaneously implanted (1 × 10^6 cells per mouse). At the endpoint, Cd38 mRNA levels in sorted tumor cells were measured by qPCR assays. The respective parental cell lines were included as the reference. mRNA levels were normalized to L32. The summarized data from 3 independent experiments are shown with P values calculated by ANOVA test. Reference, cell line; vehicle, sorted tumor cells from control vehicle-treated tumors; ATRA, sorted tumor cells from ATRA-treated tumors; BMS195614, sorted tumor cells from BMS195614-treated tumors.
CD38-Mediated Resistance to PD-1/PD-L1 Blockade

(PD-L1AG3+ and PD-L1TIM3+; Fig. 2B; Supplementary Fig. S10). The initial antitumor efficacy of short-term anti-PD-L1 antibody treatment and the temporal CD38 upregulation on resistant tumor cells caused by the infiltration of activated T cells suggests that simultaneous blockade of CD38 and PD-L1 might be required for tumor rejection. We tested this by sorting the PD-L1KOS31LN3 cells or PD-L1KOLC-JSP cells for high and negative CD38 surface staining and found that the PD-L1KOCD38+ cells did not form tumors upon implantation into immune competent mice, whereas PD-L1KOC531LN3+ cancer cells resulted in large primary tumors, numerous metastases, and rapidly aggressive disease (Fig. 2C; Supplementary Fig. S11A-S11F). To test the effect of CD38 on cancer cell growth, we measured in vitro growth rate and cell cycle, but found no difference between PD-L1KOC38+ and PD-L1KOC531LN3+ cancer cells (Supplementary Figs. S11G-S11H). By contrast, when CD8+ T cells were depleted, PD-L1KOC38+ cancer cells developed tumors and metastasized

Figure 2. CD38 on tumor cells suppresses CD8+ T-cell function. A, Growth of subcutaneous 344SQ tumors in immune-competent 129/Sv mice treated with IgG control, anti-PD-L1 (clone 9G2, 200 μg per mouse), anti-PD-L1 plus anti-CD8 (clone 2A3, 200 μg per mouse), respectively. Mice (n = 5 or 8) were intraperitoneally treated with the antibody once a week for 7 weeks beginning on day 7 after the tumor cell injection (1 × 10⁶ cells per mouse). In the group of anti-PD-L1 plus anti-CD8 treatment, mice were pretreated with anti-CD8 antibody (400 μg per mouse) 1 week before tumor cell injection. Tumor sizes are presented as mean ± SEM and statistical significance (ns, no significant difference; *, P < 0.05; **, P < 0.01) determined on indicated weeks. The statistically significant differences between the groups of control and anti-PD-L1 are as follows: week 1, ns; week 2, *; week 3, **; week 4, **; week 5, *; week 6, *; week 7, ns; week 8, ns. ANOVA test was used to calculate the significant difference between two groups. For the analysis among multiple groups at the endpoint (week 8), ANOVA was used to analyze; *, P < 0.05. B, FACS analysis of % CD8+ tumor infiltrating lymphocyte (TIL), the proliferation marker Ki67, surface CD44, CD62L, PD-1, LAG3, and TIM3 marker expression levels on CD8+ T cells from primary tumors in 129/Sv mice (n = 5) treated with anti-PD-L1 antibody at week 5. Data are shown as mean ± SEM. t test was used to analyze. C, PD-L1KOC38+S31LN3 cells or PD-L1KOC38+S31LN3 cells (5 × 10⁶ cells per mouse) were subcutaneously injected into immune competent 129/Sv mice (n = 5). The primary tumor sizes at week 4 are shown with mean ± SEM. t test was used to analyze. D, Left, CD8T cells in spleen were determined 2 weeks after initial anti-CD8 antibody injection to test CD8+ T-cell depletion efficiency. Middle, 5 × 10⁶ of PD-L1KOC38+S31LN3 cells were subcutaneously injected into 129/Sv mice (n = 5) after CD8+ T cells were depleted (α-CD8). The T-cell undepleted group was included as the control (IgG). The total tumors were measured 4 weeks after tumor cell transplantation and are shown with mean ± SEM. t test was used to analyze. Right, 5 × 10⁶ of PD-L1KOC38+S31LN3 cells were subcutaneously injected into 129/Sv mice (n = 10) after CD8+ T cells were depleted (α-CD8). The T-cell undepleted group was included as the control (IgG). The total tumors from primary site and peritoneal cavity were measured 5 weeks after tumor cell transplantation and are shown with mean ± SEM. t test was used to analyze. E, To prepare CD8+ T cells, 129/Sv mice were challenged with 0.5 × 10⁶ 344SQ for 2 weeks. CD8+ T cells were isolated from these tumors, blood, and spleens. A separate cohort of 344SQ tumor-bearing mice were treated with anti-PD-L1 antibody or control (as described in Fig. 1A), and then used as recipients for the CD8+ T-cell adoptive transfer assay. At week 4, mice received cyclophosphamide at 100 mg/kg intravenously 6 hours before CD8+ T-cell transfer (6 × 10⁶ per mouse, intravenously), followed by IL2 (20,000 units, intraperitoneally) at 8 hours after T-cell transfer then every 12 hours for 3 days. The tumor growth curves are shown on the left. At the endpoint, mice were necropsied to harvest primary tumors and lungs, which were weighed, and to quantify distant metastases. The primary tumor weights and lung metastatic nodules are shown in the middle and right panels. ANOVA test was used to analyze. (continued on next page)
whereas PD-L1KOCD38hi cancer cells developed tumors similarly in both groups (Fig. 2D, Supplementary Fig. S12A). When PD-L1KOCD38hi and PD-L1KOCD38lo cancer cells were injected into RAG2−/− mice, both tumor cell types formed tumors without significant differences (Supplementary Fig. S12B). Additionally, the development of resistance to the anti–PD-L1 treatment was inhibited by adoptive transfer of CD8+ T cells (Fig. 2E). Collectively, these data indicate that CD38 promotes tumor progression via the suppression of CD8+ T-cell function.

To further determine whether manipulating CD38 is sufficient to suppress CD8+ T-cell function and control tumor, we used KP and LLC lung cancer lines to generate models with CD38 knockdown (KD) or constitutive expression and confirmed the CD38 expression levels by qRT-PCR, western blotting, and FACS analysis (Fig. 2F and G; Supplementary Fig. S13A, S13B, and S13G). The effect of these cancer cells with CD38 knockdown (KD) or constitutive expression and TNFα (α) and IFNγ (γ) expression were cultured with specific CD8+ T cells. Tumor cells only were included as the control. T-cell killing efficiency is shown in J. The experiments were repeated at least 3 times. P values were calculated with ANOVA test. (continued on following page)
Consistent with the in vivo suppressive effects of CD38 on CD8+ T-cell function, the in vitro results provide direct evidence of CD38 inhibition on CD8+ T-cell function (Fig. 2H–M; Supplementary Fig. S13C–S13E and 13H–S13J). In the KP-derived lung cancer line 531LN3 we observed similar results with coculture assays using the sorted populations for PD-L1WT/CD38hi, PD-L1WT/CD38lo, PD-L1KO/CD38lo, and PD-L1KO/CD38hi (Fig. 2N–O).

We further observed that the growth of CD38 KD tumors (344SQ-shCD38) was slowed, with significant reduction in primary tumor size and lung metastatic lesions compared with control 344SQ_scr tumors (Fig. 3A). In contrast, 344SQ tumors with constitutive CD38 overexpression (344SQ_CD38) grew faster and produced larger primary tumors and more lung metastases than the vector control (344SQ_vector; Fig. 3B). In addition, the tumor microenvironment of each model displayed distinct and consistent immune repertoire changes upon genetic manipulation of CD38 expression on tumor cells. We observed significantly lower levels of total CD8+ T and IFNγ/CD8+ T-cell infiltrates, and higher percentages of exhausted PD-1+TIM3+CD8+ T cells in CD38-expressing tumors (Fig. 3C–H). Similar results of tumor growth and immune cell profiling were obtained in C57BL/6 animals with LLC-JSP tumors and in 129/Sv animal model with KP-derived 531LN3 tumors (Fig. 3I; Supplementary Fig. S13F and S13K; Table 1). To exclude that these observations resulted from an impact of tumor size on immune phenotype, we tested adjusted cancer cell numbers of CD38 KD, CD38 WT, and CD38 overexpression (OE) and chose tumors of similar size to analyze the CD8+ T-cell infiltration and their function. The data indicate that CD38 has a significant impact on CD8+ T-cell function regardless of tumor size or growth rate (Supplementary Fig. S14).

Our data demonstrate that CD38-expressing tumor cells impair CD8+ T-cell function. Based on the previously reported enzymatic functions of CD38 as part of an ectoenzyme complex that plays an important role in adenosine production (6), we used mass spectrometry analysis of tumor samples and found a ~2.5- to 6-fold increase in adenosine concentration in anti–PD-L1 versus control-treated tumors (Fig. 3J). Because adenosine can suppress T-cell function in the tumor microenvironment (6, 26–29), we focused on the effects of adenosine for further study. We first compared adenosine concentrations in the supernatants of three different tumor cell cultures with models that had CD38 knockdown (KD), wild-type expression (WT), or constitutive
Figure 3. CD38 regulates tumor growth and metastasis by adenosine-mediated CD8+ T-cell suppression. A, 344SQ-scr or 344SQ-shCD38 cells (2×10^6 cells per mouse) were subcutaneously injected into immune competent 129/Sv mice (n = 5). Tumor size was measured weekly and tumor growth curves are shown on the left, with tumor sizes presented as mean ± SEM. ns, no significant difference; *, P < 0.05; **, P < 0.01. The primary tumor mass and lung metastatic nodules are shown in the middle and right panels 4 weeks after injection. B, 344SQ_vector or 344SQ_CD38 cells (1×10^6 cells per mouse) were subcutaneously injected into syngeneic mice. Tumor size was measured weekly and tumor growth curves are shown on the left, with tumor sizes presented as mean ± SEM. ns, no significant difference; *, P < 0.05. The primary tumor mass and lung metastatic nodules are shown in the middle and right plots 5 weeks after injection. C-E, At the endpoint, CD8+TILs in primary tumors (344SQ-scr or 344SQ-shCD38) were analyzed by FACS and are shown in C. The percentage of exhausted CD8+ T cells measured by PD-1+TIM3+ is shown in D. Representative plots of individual tumors are shown on the left and bar graphs of the summary data for all tumors on the right (n = 5/group). F-H, At the endpoint, CD8+TILs in primary tumors (344SQ_vector or 344SQ_CD38) were analyzed by FACS and are shown in F. The percentage of exhausted CD8+ T cells measured by PD-1+TIM3+ is shown in G. The percentage of antitumor IFNγ+CD8+ population is shown in H. Tumor sizes were measured weekly and tumor growth curves are shown. Tumor sizes are presented as mean ± SEM. t-test is used to analyze the difference. ns, no significant difference; *, P < 0.05; **, P < 0.01; ***, P < 0.001. (continued on following page)
Figure 3. (Continued) J, The indicated tumor-bearing mice were treated with anti–PD-L1 antibody (Ab) or an IgG control (IgG, 200 μg intraperitoneally) once a week for 4 weeks beginning on day 7 after tumor cells were subcutaneously implanted (1×10⁶ cells per mouse). Tumor lysates were used to measure the concentration of adenosine using the Agilent Triple Quad (QQQ) 6460 Mass Spectrometer. The concentrations of adenosine in tumors are presented as mean ± SD. ****, P < 0.0001. K, 1×10⁶ of indicated cells were cultured in 100 mm tissue culture dishes for 3 days. Cells were then treated for 30 minutes with 100 μmol/L adenosine deaminase inhibitor EHNA before being cultured in the presence of 50 μmol/L NAD. Supernatants were collected after 1-hour incubation with NAD⁺ for determining adenosine concentration by mass spectrometry. The data from triplicates are shown as mean ± SEM. *, P < 0.05. ANOVA test was used to analyze. ns, no significance; **, P < 0.01; ***, P < 0.001. KD, CD38 knockdown; WT, CD38 wild-type; OE, CD38 overexpression. L, 1×10⁶ of indicated cells were cultured in the presence of anti-CD38 (30 μg/mL) or isotype control for 3 days. Cells were then treated for 30 minutes with 100 μmol/L adenosine deaminase inhibitor EHNA before being cultured in the presence of 50 μmol/L NAD⁺. Supernatants were collected after 1-hour incubation with NAD⁺ for determining adenosine concentration by mass spectrometry. The data from triplicates are shown as mean ± SEM. ANOVA test was used to analyze. ns, no significance; *, P < 0.05; **, P < 0.01; ***, P < 0.001. KD, CD38 knockdown; WT, CD38 wild-type; OE, CD38 overexpression. M, 1×10⁶ of tumor cells (left for 344SQ, middle for LLC-JSP, and right for 531LN3, respectively) were subcutaneously injected into syngeneic mice. Two weeks later, CD8⁺ T cells were sorted from tumors for determining mRNA level of adenosine receptors Adora1, Adora2a, and Adora2b by qPCR assays. mRNA levels were normalized to L32. The experiments were repeated 3 times. T cells were included as the control. T-cell proliferation was quantified using FACS analysis. The pooled data from 3 independent experiments are shown as mean ± SEM. ns, no significant difference; ***, P < 0.001; *****, P < 0.0001. ANOVA test was used to analyze. KD, CD38 knockdown; WT, CD38 wild-type; OE, CD38 overexpression; anta, indicates the addition of the antagonist cocktail against ADORA1, ADORA2a, and ADORA2b.
CD38 expression (OE). In all three tumor models, CD38 expression level strongly correlated with increased adenosine (Fig. 3K), whereas adenosine was blocked with anti-CD38 antibody (Fig. 3L), establishing a causal association between CD38 and adenosine. Previous reports suggested that inhibition of CD8⁺ T-cell function by adenosine occurs through interaction with adenosine receptors ADORA2a and ADORA2b (26). We next challenged mice with different cancer lines and sorted the CD8⁺ tumor-infiltrating lymphocyte (TIL) cells to perform qRT-PCR for ADORAI, ADORA2a, and ADORA2b expression. ADORAI was expressed at low levels, but ADORA2a and ADORA2b were highly expressed on the tumor-infiltrating CD8⁺ T cells (Fig. 3M). We functionally tested whether receptor antagonists could block CD38-mediated T-cell suppression. T-cell coculture assays with the three tumor models demonstrated that the combined adenosine receptor antagonists effectively reversed the suppressive effect of tumor cell CD38 on T-cell proliferation (Fig. 3N), indicating that CD38-mediated production of adenosine inhibits CD8⁺ T-cell proliferation through adenosine receptor signaling on CD8⁺ T cells.

Tumor Cell Lines and Patient Tumors Express CD38, Associated with Expression of Multiple Immune Checkpoints and an Active Intratumoral Immune Cell Infiltrate

The data from the murine models suggested that increased CD38 expression on tumor cells may represent an escape mechanism from the infiltrating cytotoxic T cells induced by anti–PD-L1/PD-1 therapy. To understand if this is a generalizable phenomenon, we stained for CD38 and performed FACS analysis on a panel of cancer cell lines representing lung cancer, melanoma, breast cancer, and sarcoma. Notably, 12 of 13 murine lines highly express CD38 (Fig. 4A). Additional FACS and western blotting analysis of NSCLC lines derived from a variety of patients with lung cancer showed surface CD38 expression on most of the lines (Fig. 4A; Supplementary Fig. S15A). We next used two independent tissue microarrays of early-stage lung cancer specimens to analyze CD38 expression by immunohistochemical staining [259 specimens from the MD Anderson PROSPECT data set (TMA3) and a separate set of 534 specimens (TMA4)]. We validated and used a monoclonal antibody specifically recognizing CD38 to determine the membranous protein expression only on cancer cells in the TMA specimens (Supplementary Fig. S15B). Of the 259 TMA3 specimens, 209 had qualified staining and 23% exhibited positive staining for CD38 on tumor cells, whereas of the 534 TMA4 specimens, 471 had qualified staining and 15% exhibited positive staining for CD38 on tumor cells (Fig. 4B and F; Supplementary Fig. S15F; Supplementary Tables S7 and S8). We have corresponding total tumor mRNA expression data for 165 samples in the TMA3 cohort and found a broad distribution of CD38 mRNA expression in the samples. Importantly, there was a strong correlation between IHC score of protein levels and mRNA expression (R² = 0.613 × 10⁻⁷; Fig. 4C). The fact that some tumors with low tumor cell membrane staining displayed high mRNA levels is probably due to the presence of CD38 on infiltrating cell populations in the tumors.

Given the strong correlation between CD38 mRNA and CD38 protein levels, we turned to other available patient data sets for which only mRNA expression data are available to perform additional analyses, including the lung cancer and melanoma data sets from The Cancer Genome Atlas (TCGA; lung adenocarcinoma, n = 512; lung squamous carcinoma, n = 496; melanoma data set, n = 469), and the MD Anderson BATTLE-2 trial (metastatic lung cancer, n = 144). Ranking of the samples by CD38 mRNA levels revealed relatively high levels in about ~25% to 30% of cases, with a strong correlation between CD38 expression and a previously described immune inflammatory signature (30) that includes multiple markers of immune-suppressive cell types and known immune checkpoint molecules and cytokines, e.g., FOXP3, CTLA4, PD-1, LAG3, TIM3, PD-L2, HVEM, BTLA, IDO, and CCL2 (Fig. 4D; Supplementary Fig. S15C–S15D; Supplementary Tables S9 and S10). The data from lung cancer and melanoma data sets demonstrate a strong correlation between CD38 expression and a cytolytic T-cell tumor infiltrate (Fig. 4E; Supplementary Fig. S15E), consistent with the animal and in vitro coculture studies (Fig. 1D–H; Supplementary Fig. S3). To further define the immune subsets of untreated tumors based on CD38 and PD-L1
expression, we performed IHC staining of PD-L1 in the same 793 early-stage tumors from the tissue microarrays [TMA3 (259 cases) and TMA4 (534 cases)] and found that 10.2% to 16.7% expressed high levels of both, whereas 0.1% to 6.7% expressed high CD38 but low PD-L1. Roughly 50% of these untreated tumors had high PD-L1 staining and low CD38 (Fig. 4F; Supplementary Fig. S15F; Supplementary Tables S7 and S8). Interestingly, although CD38 was reported as a (259 cases) and TMA4 (534 cases)] and found that 10.2% to 16.7% expressed high CD38 but low PD-L1. Roughly 50% of these untreated tumors had high PD-L1 staining and low CD38 (Fig. 4F; Supplementary Fig. S15F; Supplementary Tables S7 and S8). Interestingly, although CD38 was reported as a prognostic biomarker in multiple myeloma (7), and PD-1/PD-L1 expression in lung cancer patient samples from TCGA (n = 1,008), MD Anderson PROSPECT (n = 275), and MD Anderson BATTLE-2 (n = 144) data sets. Spearman correlation test is applied on each gene to check the association with mRNA levels of CD38. Adjusted P value < 0.05 and Spearman rho ≥ 0.5 were used as the criteria to select the most significant immune markers for generating the heat map. E, Spearman rank correlation (ρ) was used to assess the association between T-cell cytolytic score and CD38 expression in lung cancer patient samples from TCGA (n = 1,008), MD Anderson PROSPECT (n = 275), and MD Anderson BATTLE-2 (n = 144) data sets. T-cell cytolytic score was computed as described in ref. 49. (continued on next page)
vs. progressive disease + stable disease) to PD-1 checkpoint blockade, with higher CD38 levels predicting lack of response (Supplementary Fig. S17A–S17C). Subcategorization by both PD-L1 and CD38 levels was not predictive of response (Supplementary Fig. S17A–S17C). Subcategorization by both PD-L1 and CD38 levels was not predictive of response (Supplementary Fig. S17A–S17C).

We further evaluated a melanoma data set where RNA-seq data are available for tumor biopsy specimens (n = 43 pairs) pretreatment and on-treatment with nivolumab (anti–PD-1) and observed that CD38 expression correlates with the activated CD8+ T-cell status of the tumors in both pre- (n = 51) and on-treatment samples (n = 56; Fig. 4G). Additionally, CD38 levels are increased in response to treatment (mean: pretreatment −0.03, posttreatment 0.04, P = 0.019 by paired t test; Fig. 4H). Overall, these findings from more than 2,500 primary or metastatic lung and melanoma tumors demonstrate that CD38 is found at moderate to high levels in a large percentage of tumors and is expressed in tumors with an active immune cell infiltrate and in which multiple immune modulators (e.g., PD-L1) are expressed, and are consistent with CD38 being upregulated as a consequence of the natural or treatment-mediated immune/inflammatory reaction in the tumor microenvironment.

**Combination Blockade of PD-L1 and CD38 Improves Antitumor Immune Responses**

Due to the upregulation of CD38 expression after PD-L1/ PD-1 blockade and the subsequent suppressive effect on CD8+ T cells, we assessed the therapeutic efficacy of CD38 inhibitors (anti-CD38 antibody or the biological flavonoid Rhein, which is an enzymatic inhibitor; ref. 31) in combination with anti–PD-L1 antibody in tumor models. Concurrent CD38 inhibition with anti-CD38 antibody (clone NIMR-5)
and anti-PD-L1 antibody suppressed primary tumor growth and metastases more than either monotherapy alone or isotype treatment (Fig. 5A–C; Supplementary Table S12). When tumor-bearing mice were treated with anti-CD38 antibody, tumor growth was significantly inhibited. However, this inhibition was reversed after CD8⁺ T-cell depletation, demonstrating that CD38 works in a CD8⁺ T cell–dependent manner (Supplementary Fig. S18). Although neither CD38 nor PD-L1 inhibition alone significantly reduced the number of metastatic lung nodules, they did reduce the metastatic tumor size, whereas the combination treatment reduced both metastatic tumor number and metastatic tumor size. Similar results were obtained with combination therapy of anti–PD-L1 antibody and the flavonoid Rhein, which inhibits CD38 enzymatic activity (Fig. 5D; Supplementary Fig. S19A; Supplementary Table S12). Strikingly, combination genetic and pharmacologic blockade using the PD-L1KO531LN3 cells sorted for high CD38 expression and treated with Rhein completely and rapidly eradicated the tumors (Fig. 5E), similar to the results with the PD-L1KO531LN3 cells sorted for negative CD38 expression (Fig. 2D). Immune profiling of tumors from each single and

**Figure 5.** Coinhibition of PD-L1 and CD38 or adenosine signaling improves antitumor immune responses. A, The indicated antibody or the isotype-matched IgG control was injected into 129/Sv mice (intraperitoneally) once a week for 7 weeks beginning on day 7 after subcutaneous 344SQ tumor cell injection (1 × 10⁶ cells per mouse; n = 5/group). Dosing per injection was 200 μg of anti–PD-L1; 250 μg of anti-CD38. Tumors were measured once a week for 8 weeks. The tumor growth curves are shown on the left. The final tumor weights and metastatic lung nodules are shown in the middle and right. P values were calculated with ANOVA test. B, Representative hematoxylin and eosin–stained lung tissues from each group of A are shown, indicating metastatic nodules. Scale bars, 600 μm. C, The indicated antibody was injected into C57BL/6 mice (intraperitoneally) once a week for 5 weeks beginning on day 7 after subcutaneous LLC-JSP tumor cell injection (1 × 10⁶ cells per mouse). Dosing per injection was 200 μg of anti–PD-L1; 250 μg of anti-CD38. Combination represents the combination of 200 μg anti–PD-L1 and 250 μg anti-CD38. Tumors were measured once a week for 6 weeks. The tumor growth curves are shown. D, C57BL/6 mice were treated with anti–PD-L1 and Rhein (CD38 inhibitor) once a week for 5 weeks beginning on day 7 after the subcutaneous LLC-JSP tumor cell injection (1 × 10⁶ cells per mouse). Dosing per intraperitoneal injection was 200 μg of anti–PD-L1; 50 mg/kg of Rhein. Tumors were measured once a week for 6 weeks. The tumor growth curves are shown (n = 5/group). E, PD-L1KO531LN3 cells (2 × 10⁶ cells per mouse) were subcutaneously injected into immune competent 129/Sv mice (n = 5/group). Mice were treated with Rhein (CD38 inhibitor) once a week for 4 weeks beginning on day 1 after tumor cell injection. Dosing per intraperitoneal injection was 50 mg/kg. Tumors were measured once a week for 5 weeks. The tumor growth curves are shown on the left and the final tumor weights are shown on the right. Tumor sizes are presented as mean ± SEM. ns, no significant difference; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. F, FACs analysis of CD4⁺ICOS⁺TIL and CD4⁺TIL frequency, percentage of memory CD8⁺ T cells and exhausted CD8⁺ T cells, and tumor-infiltrating Tregs and MDSCs from the endpoint primary tumors of A. The statistical summary is shown. ns, no significant difference; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. P values were calculated with ANOVA test. The gating strategies are included in the legend of Supplementary Fig. S20.
Figure 5. (Continued) G (Left), CD38 mRNA levels in murine lung cancer cell lines 344SQ, LLC-JSP, and 307P were determined by qPCR assays. mRNA levels are normalized to L32. The experiments were repeated at least 3 times. Middle, CD38 protein levels in murine lung cancer cell lines 344SQ, LLC-JSP, and 307P were determined by western blotting. β-Actin was used as the loading control. Right, 4 × 10^6 of 307P cells were subcutaneously injected into 129/Sv mice (n = 3). CD38 expression on sorted 307P tumor cells (CD31+CD45+EPCAM+) for sorting) was determined by FACS analysis 2 weeks after cancer cell injection. The representative histogram is shown. Red, isotype staining; light blue, CD38 staining. H, 129/Sv mice were treated weekly with anti–PD-L1 (200 μg per mouse), anti–PD-1 (200 μg per mouse), or their IgG control beginning on day 7 after a subcutaneous 307P cancer cell injection (4 × 10^6 cells per mouse; n = 5 or 7) for indicated weeks. The tumor growth was monitored once a week. The tumor growth curves are shown. I, Left, 129/Sv mice were treated weekly with anti–PD-L1 (200 μg per mouse) or IgG control (Control) beginning on day 7 after a subcutaneous 344SQ cancer cell injection (0.05 × 10^6 cells per mouse; n = 5) for 6 weeks. Mice in one of anti–PD-L1 treatment groups were sequentially treated with anti–PD-1 (250 μg per mouse) once a week for 4 weeks. The tumor growth was monitored once a week. The tumor growth curves are shown. Right, C57BL/6 mice were treated weekly with anti-CD38 (250 μg per mouse) or IgG control (Control) beginning on day 7 after a subcutaneous LLC-JSP cancer cell injection (0.05 × 10^6 cells per mouse; n = 5 or 7) for 6 weeks. The tumor growth was monitored once a week. The tumor growth curves are shown. J, 200 μg of anti–PD-L1 antibody or the isotype-matched IgG control was intraperitoneally injected into mice (n = 5 or 7) once a week, whereas A2R anta (2 mg/kg of SCH 58261 and 1 mg/kg of PSB 1115) in 100 μL of carrier solution were intraperitoneally injected every other day, for the indicated weeks beginning on day 7 after subcutaneous tumor cell injection (1 × 10^6 cells per mouse). The mice in control group received both IgG control and carrier solution. Tumors were measured once a week and the tumor growth curves are shown. A2R anta, adenosine receptor 2 antagonists; SCH 58261, A2a adenosine receptor antagonist; PSB 1115, A2b adenosine receptor antagonist. K, The working model of CD38 as a major mechanism of the resistance to PD-1/PD-L1 blockade.
CD38-Mediated Resistance to PD-1/PD-L1 Blockade

**Table 2. Coinhibition of PD-L1 and CD38 produces a favorable antitumor microenvironment**

<table>
<thead>
<tr>
<th>Infiltrating immune cells in LLC-JSP-bearing tumors</th>
<th>Combination therapy of anti–PD-L1 and anti-CD38</th>
<th>Combination therapy of anti–PD-L1 and Rhein</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of CD8(^+) T cells</td>
<td>Control</td>
<td>anti–PD-L1</td>
</tr>
<tr>
<td>% of CD44(^\text{hi}) CD62L(^\text{hi}) in CD8(^+) T cells</td>
<td>50.90 ± 1.90</td>
<td>46.10 ± 1.18</td>
</tr>
<tr>
<td>% of PD-1(^+) TIM3(^+) in CD8(^+) T cells</td>
<td>30.43 ± 2.17</td>
<td>38.53 ± 2.98</td>
</tr>
<tr>
<td>% of CD4(^+)ICOS(^+) T cells</td>
<td>4.27 ± 0.46</td>
<td>6.26 ± 0.53</td>
</tr>
<tr>
<td>% of Tregs in CD4(^+) T cells</td>
<td>10.63 ± 0.45</td>
<td>13.90 ± 0.54</td>
</tr>
<tr>
<td>% of MDCSs in CD45(^+) cells</td>
<td>24.38 ± 1.98</td>
<td>30.53 ± 1.01</td>
</tr>
</tbody>
</table>

Combination therapy revealed that more total and activated CD8\(^+\) T cells, more memory CD8\(^+\) T cells (CD44\(^\text{hi}\)CD62L\(^\text{hi}\)), increased CD4\(^+\)ICOS\(^+\) T cells, and less infiltration of CD4\(^+\) regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC) were observed in the combination therapies with anti–CD38 than in single or control treatments (Fig. 5F; Supplementary Figs. S19B and S20; Table 2). Additionally, in a KP tumor model naturally CD38-deficient and unable to upregulate CD38 expression (307P), we observed that anti–PD-1/PD-L1 monotherapy monitors dramatically inhibited tumor growth or eliminated tumors (Fig. 5G–H). Although therapeutic treatment with anti–CD38 antibody or the enzymatic inhibitor does not distinguish between the effects of tumor cell and host cell CD38, the data demonstrate that systemic treatment has similar efficacy in reprogramming the immune microenvironment of the tumor as genetic manipulation of CD38 on tumor cells and does not engender systemic toxicity or antagonism that compromises the therapeutic effects.

To model how CD38-blocking strategies might be translated into the clinic for patients with disease refractory to anti–PD-1/PD-L1, we tested sequential treatment after the development of resistance to anti–PD-L1 by treating animals with anti–CD38 antibody alone. We observed a substantial inhibition of tumor growth with an associated enhancement of the effector CD8\(^+\) and CD4\(^+\) T-cell responses and blunting of the suppressor CD4\(^+\) Treg and MDSC populations, highlighting that CD38 is an independent factor in treatment-induced resistance (Fig. 5I; Supplementary Fig. S22B). Interestingly, we found that CD38 was internalized after treating lung cancer cells with NIMR-5 (Supplementary Fig. S22C), consistent with the abrogation of adenosine levels upon treatment noted in Fig. 3L. Finally, given our data that CD38 suppresses CD8\(^+\) T-cell function via adenosine receptor signaling, and the ongoing development of A2R inhibitors for cancer treatment (34), we tested the potential benefits from combination A2R antagonists and anti–PD-L1. We observed significant improvements of antitumor effect with A2R antagonists alone or combined with anti–PD-L1 (Fig. 5J), which confirms the strong role of adenosine signaling on CD8\(^+\) T-cell function. Overall, the therapeutic studies demonstrate that combination CD38 and PD-L1 blockade substantially reduces primary tumor burden and metastases, that CD38 can be used in combination or in a sequential manner upon the acquisition of resistance, and that targeting CD38 or the downstream adenosine signaling is highly effective.

**DISCUSSION**

Immune checkpoint therapies have gained significant attention for their clinical potential to improve durable outcomes for patients with cancer (35, 36). However, only a fraction of patients derive long-term benefit, and extensive efforts are ongoing to understand the underlying mechanisms of response/resistance. Analyses of experimental models and patient tumors have demonstrated that both de novo and acquired immune checkpoint inhibitor resistance arise from a number of tumor cell–intrinsic and –extrinsic mechanisms (3). Many of these mechanisms occur as a dynamic response of the tumor or microenvironment to an effective T-cell infiltration. Herein we found that when animal models were treated for an extended period with anti–PD-1 or anti–PD-L1 therapy, acquired resistance developed after an initial suppression of tumor growth and metastases, independent of the tumor type and strain background. This resistance was...
observed in response to both pharmacologic and genetic PD-1/PD-L1 blockade in lung cancer and melanoma models, and in each case we found that CD38 was upregulated on tumor cells. We also found associated functional impairment of CD8+ T cells after their initial activation and expansion, demonstrating a novel parallel role for CD38 within the microenvironment of T cell-inflamed tumors to drive adaptive immune escape. The data demonstrate that CD38 upregulation after PD-1/PD-L1 blockade is neither genotype- nor histology-dependent, suggesting that CD38-mediated resistance could occur in a broad variety of cancer types.

Because CD38 expression was induced upon PD-1/PD-L1 blockade, we hypothesized that CD38 upregulation results from intratumoral T-cell infiltration and associated changes in the cytokine/metabolite milieu. Indeed, we found a strong correlation between CD8+ T cells and CD38 expression in NSCLC and melanoma. Additionally, when tumor cells were cultured in vitro with activated CD8+ T cells, CD38 was upregulated. In anti–PD-L1 antibody–treated tumors, we observed increased ATRA levels, which regulate IRF1 and downstream IFNβ production (24, 25), and could recapitulate the effect of ATRA on CD38 upregulation by pharmacologic dosing or antagonism, consistent with previous reports that ATRA and IFNβ are enriched in inflammatory tumors and serve as potent inducers of CD38 (17, 18, 24, 25). This study uncovered a new insight into how ATRA regulates T-cell immunity via CD38 and the production of adenosine. Taken together, our current study emphasizes that the tumor immune microenvironment undergoes an adaptive reprogramming under the continued pressure of PD-L1/PD-1 axis blockade. Either preexistent or upregulated CD38 expression in tumor cells is responsible for this adaptive immune shift in response to anti–PD-1/anti–PD-L1 antibody treatment, and over time the immunosuppressive effect of CD38+ tumor cells becomes dominant over PD-L1.

CD38 has long been considered an immune molecule because it is expressed on activated B, T, and natural killer cells (7). However, several recent studies have suggested a broader distribution and more complex role, based upon its multifunctional activities (6). For example, a report showed that CD38+CD8+ T lymphocytes have strong immunosuppressive capabilities. This subset possesses a regulatory potential that could work together with the innate immune response and control immune homeostasis (37). Another group reported that CD38+ MDSCs possess the capacity to suppress activated T cells and promote tumor growth to a greater degree than CD38− MDSCs (11). CD38 has also been associated with functions exerted by Tregs, in which high CD38 expression in FOXP3+/CD4+ T-cell populations correlates with extremely powerful modulatory properties of CD4+ regulatory T lymphocytes (38). Consistent with these findings, when Feng and colleagues evaluated percentages of CD38-expressing Treg subsets from normal donors and patients with myeloma, they found a high expression of CD38 on CD4+CD25+FOXP3+ regulatory T cells, and that targeting CD38 could block this immunosuppressive population (39). In addition, the noncanonical adenosinergic pathway led by CD38/CD203a provides substrates to CD73 and consequently feeds the production of the potent immunosuppressor adenosine, which is normally essential in maintaining tissue homeostasis and preventing an overzealous immune response (7, 40, 41). Morandi and colleagues have shown that primary human melanoma cell lines can take advantage of this ectoenzyme complex to suppress T-cell proliferation through adenosine production (26). Another recent study demonstrated a role for NAD+ levels, which are regulated by CD38 on T cells, as an important factor in the reprogramming of intratumoral CD4+ cells into hybrid effector Th1/17 cells for enhanced adoptive T-cell therapy (42). In this study, we have identified CD38 as an immune-suppressive molecule expressed on cancer cells allowing their adaptive escape from checkpoint inhibitor–mediated immune attack through the adenosine production pathway, thereby promoting resistance to anti–PD-L1/PD-1 therapy, as shown schematically in the model (Fig. 5K). The emerging evidence suggests a multifaceted immunosuppressive role for CD38 in regulating the tumor immune microenvironment.

The identification of biomarkers that predict response to immune therapy or identify individuals most likely to develop resistance is a key goal in the clinical use of single-agent and combination therapies. Our observations from the clinical data sets of a strong correlation between CD38 expression and an immune infiltrated tumor suggest that CD38 might serve as an appropriate marker of adaptive immune resistance to tumor-specific T-cell infiltration rather than as a static constitutive biomarker. Although our animal model data suggest multiple potential translational strategies to overcome immune checkpoint inhibitor resistance mediated by CD38, many questions about how best to incorporate CD38 into immunotherapy strategies will need to be studied in prospective clinical trials of CD38 blockade. Although daratumumab (anti-CD38 monoclonal antibody; Darzalex) is approved by the FDA for the treatment of multiple myeloma and shows pronounced efficacy as a single-agent or combination therapy with an acceptable adverse event profile (32), there are currently no data regarding its efficacy in solid tumors. The mechanism of immune resistance to anti–PD-L1/PD-1 therapy caused by CD38 provides an evident rationale for recruitment of patients with cancer for clinical trials of anti-CD38 in combination with anti–PD-L1/PD-1 to prevent therapy resistance and further enhance antitumor efficacy.

**METHODS**

**Tumor Models and Tumor Micro-CT Scanning**

Animal studies were approved by the Institutional Animal Care and Use Committee at MD Anderson Cancer Center. To study primary tumor growth and lung metastases, cancer cells (if not indicated, 0.5 × 10⁶ for LLC-JSP; 1 × 10⁶ for 344SQ; and 2 × 10⁶ for 531LN3) in 100 μL of phosphate-buffered saline (PBS) were injected subcutaneously into the mouse flank. Tumor sizes were calculated using the formula ½(length × width × width) at indicated time points. For lung metastasis measurement, the lungs were removed and immersed in cold PBS, and nodules on the lung surface were counted as described previously (4, 5).

Spontaneous KrasLA1+/− and KrasLA1+/−/Trp53g12R172H+/− mice were bred in our laboratory, and tumor growth was measured by micro-CT scanning. Multiple transverse cross-sectional CT images were provided for analysis by ImageJ. The largest cross-sectional tumor areas were selected for quantification. Tumor diameters were measured with the
In Vivo Treatments
Mice were treated with antibodies (200 μg of anti-PD-L1 per mouse; 250 μg of anti-CD38 per mouse; or combination) and their IgG control via i.p. injection once a week for indicated weeks. Rhein (CD38 inhibitor) was used at 50 mg/kg intraperitoneally per dose once a week for indicated weeks. A total of 200 μg/mouse of anti-PD-1 antibody or an IgG control was intraperitoneally injected into mice twice a week (or 300 μg/mouse once a week) for indicated weeks beginning on day 7 after tumor cells were subcutaneously implanted.

For ATRA and its receptor antagonist treatment, tumor-bearing mice were treated with ATRA (45 μg in 100 μL 1% methylcellulose; oral administration) or RAR antagonist BMIS195614 (67 μg in 100 μL 1% methylcellulose; oral administration) once a day for 1 to 2 weeks beginning on day 4 after tumor cells were subcutaneously implanted (1 x 10⁶ cells per mouse).

For the combination treatment of A2R antagonists and anti-PD-L1, 200 μg of anti-PD-L1 antibody or the IgG control was intraperitoneally injected into mice once a week, and 2 mg/kg of SCH 58261 (A2a adenosine receptor antagonist) and 1 mg/kg of PSB 1115 (A2b adenosine receptor antagonist) in 100 μL of carrier solution (15% DMSO, 15% Cremophore EL, 70% H₂O) were intraperitoneally injected every other day, for indicated weeks beginning on day 7 after subcutaneous cell injection. The mice in the control group received both IgG control and carrier solution.

Coculture Assay
To prepare tumor-specific CD8⁺ T cells, 129/Sv mice were challenged by subcutaneous tumor cell injection with 0.5 x 10⁸ 344SQ or C57BL/6 mice with 0.2 x 10⁶ LLC-JSP for 2 weeks. CD8⁺ T cells were isolated from the tumors, blood, and spleens of these animals, and labeled with CFSE following the kit’s instructions (CellTrace CFSE Cell Proliferation Kit, catalog #CS4554, Life Technologies). CFSE-labeled CD8⁺ T cells were cocultured with the indicated cells in the presence of anti-CD3 (5 μg/mL) and anti-CD28 (5 μg/mL) for 4 days. T-cell proliferation was quantified using FACS analysis.

mRNA Expression Profiling of Cancer Patient Samples
Experimental details regarding TCGA data sets including RNA extraction, mRNA library preparation, sequencing (Illumina HiSeq platform), quality control, data processing, and quantification of gene expression were previously published (43, 44). For the PROSPECT and BATTLE-2 samples, the mRNA was extracted from frozen tumor tissue corresponding to the same specimen from which the formalin-fixed, paraffin-embedded blocks were made. Array-based expression profiling of PROSPECT tumors was performed using the Illumina HumanWG-6 v3 BeadChip, according to the manufacturer’s protocol. Gene expression data for the PROSPECT data set have been previously deposited in the GEO repository (GSE42127; refs. 30, 45). The raw data files of transcriptomes were analyzed using Bioconductor R packages. Scatter plots were generated through the cBioPortal (46, 47).

Disclosure of Potential Conflicts of Interest
D.L. Gibbons reports receiving a commercial research grant from Janssen Research and Development. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L. Chen, Y. Yang, T. Cascone, P.L. Lorenzi, F. Skoulidis, B.W. Carter, L.A. Byers, S.E. Woodman, V.A. Papadimitrakopoulou, S.E. Ullrich, L.I. Wistuba, D.L. Gibbons
Study supervision: L. Chen, F.X.-F. Qin, D.L. Gibbons

Acknowledgments
This work was supported by P50CA070907-16A1, P50CA070907-18, and the Elsa U. Pardee Foundation to L. Chen; CPRIT RP150405, CPRIT-MIRA RP166652-P3, and NCI R37CA146090-01A1 to D.L. Gibbons; CPRIT RP130397 to P.L. Lorenzi; CA087546 and CA190722 to E. Dmitrovsky; the CAMS Initiative for Innovative Medicine (2016-I2M-005) and the National Natural Science Foundation (81590765) to F.X. Qin. The work was also supported by the generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program and the MD Anderson Cancer Center Support Grant P30CA01667. We thank the members of our labs for critical discussions and the continued efforts of the lung cancer GEMINI team.

Received September 13, 2017; revised April 10, 2018; accepted July 11, 2018; published first July 16, 2018.

REFERENCES


CD38-Mediated Resistance to PD-1/PD-L1 Blockade
